Combination hepatitis C drugs curing almost all people who complete treatment, real-world studies show
Once-daily combination pills that can treat all genotypes of hepatitis C infection are curing almost everyone who completes a course of treatment, and drop-out rates during treatment are low, large 'real-world' cohort studies reported at The International Liver Congress in Vienna.
There is a dearth of data on transgender and non-binary people receiving HIV care in the UK, but Public Health England (PHE) is beginning to redress this: 123 trans people were recorded as accessing HIV care in England in 2017.
Naltrexone implants provide better HIV treatment outcomes for those with HIV and opioid addiction in Russia
A double-blind, placebo-controlled randomised trial conducted in Russia found that slow-release naltrexone implants resulted in better HIV treatment outcomes for people living with HIV and opioid dependence when compared to orally administered naltrexone.
Young people born with HIV more likely to have “mild” verbal memory test deficits if they have ever had an AIDS-defining condition
A study presented at this year’s Conference on Retroviruses and Opportunistic Infections (CROI 2019) in Seattle found that young people born with HIV performed worse when given certain neurological/psychological tasks than HIV-negative peers – but only if they had ever had what is called a CDC category C illness, which equates to having had an AIDS-defining condition in adults.
Older black HIV-positive women have more mental distress than other women with HIV, but get less help for it
A study looking at women aged over 45 living with HIV in the UK has found that while black African and Caribbean women experience greater social isolation and subjective mental distress than white women, they are less likely ever to have been diagnosed with depression or have it treated.
Analysis of men who acquired HIV in the deferred arm of the PROUD study highlights two risk factors that are far more important than any others. “A recent history of syphilis or rectal chlamydia/gonorrhoea, or multiple ncRAI [receptive anal intercourse without a condom] partners indicates a high imminent risk of HIV infection,” Ellen White of University College London and colleagues write in Sexually Transmitted Infections. “MSM with any of these characteristics should be offered PrEP as a matter of urgency.”
The US Food and Drug Administration (FDA) has approved Dovato, a new single-tablet antiretroviral regimen containing the HIV integrase inhibitor dolutegravir (sold separately as Tivicay) and the nucleoside reverse transcriptase inhibitor lamivudine.
An experimental monoclonal antibody called PGT121 led to viral suppression that lasted for up to six months in HIV-positive people who started with a low viral load, according to results from a small study presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2019).
A human papillomavirus (HPV) vaccination programme targeted at men who have sex with men (MSM) can be effectively delivered using specialist sexual health and HIV clinics, according to an analysis of an English pilot study published in Eurosurveillance. Uptake of the vaccine by eligible MSM was high, relatively few men attended specifically to receive the vaccine and there was no evidence that provision of the vaccine caused disruption to clinics.
Black men who have sex with men (MSM) in London experience a unique set of motivations and barriers to using pre-exposure prophylaxis (PrEP), according to the results of a recent qualitative study published in Sexually Transmitted Infections.